275 related articles for article (PubMed ID: 29925060)
21. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
[No Abstract] [Full Text] [Related]
22. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
[TBL] [Abstract][Full Text] [Related]
23. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient.
Micozkadioglu H; Koc Z; Ozelsancak R; Yildiz I
Ren Fail; 2010; 32(10):1233-6. PubMed ID: 20954988
[TBL] [Abstract][Full Text] [Related]
24. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD
Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292
[TBL] [Abstract][Full Text] [Related]
26. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update.
Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771
[TBL] [Abstract][Full Text] [Related]
27. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
Mutizwa MM; Berk DR; Anadkat MJ
Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
[No Abstract] [Full Text] [Related]
28. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.
Kaufman McNamara E; Curtis AR; Fleischer AB
J Dermatolog Treat; 2012 Feb; 23(1):46-8. PubMed ID: 20673154
[TBL] [Abstract][Full Text] [Related]
30. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
[TBL] [Abstract][Full Text] [Related]
31. Combined treatment of disfiguring facial angiofibromas in tuberous sclerosis complex with surgical debulking and topical sirolimus.
Patterson JL; Iyengar S; Catasus C; Kolodney JA; Zinn Z
Cutis; 2020 Dec; 106(6):307-308. PubMed ID: 33471874
[TBL] [Abstract][Full Text] [Related]
32. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
[TBL] [Abstract][Full Text] [Related]
33. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
Tu J; Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex.
Amin S; Lux A; Khan A; O'Callaghan F
Int Sch Res Notices; 2017; 2017():8404378. PubMed ID: 29270462
[No Abstract] [Full Text] [Related]
35. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.
Koenig MK; Hebert AA; Roberson J; Samuels J; Slopis J; Woerner A; Northrup H
Drugs R D; 2012 Sep; 12(3):121-6. PubMed ID: 22934754
[TBL] [Abstract][Full Text] [Related]
36. Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex.
Hatano T; Ohno Y; Imai Y; Moritake J; Endo K; Tamari M; Egawa S
Orphanet J Rare Dis; 2020 Jun; 15(1):133. PubMed ID: 32487130
[TBL] [Abstract][Full Text] [Related]
37. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
[No Abstract] [Full Text] [Related]
38. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response.
Truchuelo T; Díaz-Ley B; Ríos L; Alcántara J; Jaén P
Dermatol Online J; 2012 Jan; 18(1):15. PubMed ID: 22301052
[TBL] [Abstract][Full Text] [Related]
39. [Successful treatment of facial angiofibromas with local sirolimus in childhood in Bourneville-Pringle disease].
Bottyán K; Kemény L; Csoma ZR
Orv Hetil; 2019 Mar; 160(13):516-520. PubMed ID: 30907099
[TBL] [Abstract][Full Text] [Related]
40. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex.
Tyburczy ME; Wang JA; Li S; Thangapazham R; Chekaluk Y; Moss J; Kwiatkowski DJ; Darling TN
Hum Mol Genet; 2014 Apr; 23(8):2023-9. PubMed ID: 24271014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
